Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
- PMID: 28455946
- DOI: 10.1002/cpt.681
Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
Comment in
-
Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".Clin Pharmacol Ther. 2018 Feb;103(2):187. doi: 10.1002/cpt.811. Epub 2017 Nov 16. Clin Pharmacol Ther. 2018. PMID: 28786218 No abstract available.
-
Impact of CYP3A4 Genotype on Voriconazole Exposure.Clin Pharmacol Ther. 2018 Feb;103(2):185-186. doi: 10.1002/cpt.809. Epub 2017 Aug 29. Clin Pharmacol Ther. 2018. PMID: 28786228 No abstract available.
Comment on
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18. Clin Pharmacol Ther. 2017. PMID: 27981572 Free PMC article.
-
Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.Clin Pharmacol Ther. 2017 Aug;102(2):189. doi: 10.1002/cpt.662. Epub 2017 May 26. Clin Pharmacol Ther. 2017. PMID: 28182291 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
